Barbara Koumaras - Concepedia

Author

Barbara Koumaras

Novartis (United States)

Also Known As

B. Koumaras, Barbara Koumaras

Publications

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)Rush University Medical Center Tris Pharma (United States)Takeda (United States)

About

Barbara Koumaras is an author at Novartis (United States) specializing in alzheimer's disease, medicine, and dementia.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	152
2	Health Sciences	3	3	131
3	Neurology	3	3	133
4	Geriatrics	2	2	113
5	Nursing	1	1	19

Barbara Koumaras

Publications

988

Citations

H-Index

Page 1

	Year	Citations
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials Elizabeth Berry‐Kravis, Vincent des Portes, Randi J. Hagerman, Science Translational Medicine	2016	260
Effects of rivastigmine on cognitive function in patients with traumatic brain injury Jonathan Silver, Barbara Koumaras, M. Chen, Neurology	2006	124
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study Donald B. Bailey, Elizabeth Berry‐Kravis, Anne Wheeler, Journal of Neurodevelopmental Disorders	2015	99
Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study Jeffrey L. Cummings, Barbara Koumaras, Michael Chen, The American journal of geriatric pharmacotherapy Probable AlzheimerNeuropsychologyAlzheimer's DiseasePsychiatryGeriatrics	2005	94
Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial Martin R. Farlow, Steven G. Potkin, Barbara Koumaras, Archives of Neurology	2003	73
Long-term effects of rivastigmine capsules in patients with traumatic brain injury Jonathan Silver, Barbara Koumaras, Xiangyi Meng, Brain Injury	2009	64
Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study Peter M. Aupperle, Barbara Koumaras, Michael Chen, Current Medical Research and Opinion	2004	55
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents Randi J. Hagerman, Sébastien Jacquemont, Elizabeth Berry‐Kravis, Scientific Reports	2018	46
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26‐week, open‐label, prospective trial (Study ENA713B US32) Jason T. Olin, Vinod Bhatnagar, Patricio F. Reyes, International Journal of Geriatric Psychiatry	2009	41
Switching from Donepezil Tablets to Rivastigmine Transdermal Patch in Alzheimer's Disease Carl Sadowsky, Alan Dengiz, Jason T. Olin, American Journal of Alzheimer s Disease & Other Dementias®	2009	40

Page 1